The Results of Phase I Clinical Trial of the Araclon Biotech Alzheimer's Vaccine Support Its Continuation
The conclusions of the trial were presented at the Alzheimer's Association International Conference in Toronto. The compound ABvac40, designed...
FDA Approves Grifols Prolastin®-C Liquid [Alpha-1 Proteinase Inhibitor, Liquid] for the Treatment of Alpha-1 Antitrypsin Deficiency
Prolastin®-C Liquid is the first liquid formulation of an alpha-1 antitrypsin deficiency replacement therapy manufactured in the U.S. The new...
Grifols Obtains Exclusive Rights to Market and Distribute MassBiologics' Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine in U.S.
Grifols is the only company in the U.S. that offers two tetanus therapies, providing patients at risk for tetanus with both passive and active...
Procleix® Zika Virus Assay Approved by the FDA for Blood Screening on the Procleix® Panther® System
Procleix Zika Virus assay approved for the detection of viral RNA in plasma and serum specimens, previously used since June 2016 under IND...
Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System
07.02.2019
New assay enables blood banks to screen for the Babesia parasite in donated blood
Babesia transfusion-transmitted infections (TTIs)...
Grifols agrees long term loan with the European Investment Bank
Grifols is one of the first companies to receive funding from the European Investment Bank (EIB) through the new European Fund for Strategic...
Grifols Will Invest USD 360M to Expand Its Manufacturing Capacities for Plasma-Derived Therapies
Grifols' Board of Directors approves a plan for new industrial investments for the Bioscience Division to ensure the company's long-term...
Sales of the Bioscience Division Grow by +7.0%, Increasing Grifols' Revenues by +2.7% to EUR 1,952 Million
Strong positive growth for the four main plasma proteins, that jointly with the others, take the revenues of the Bioscience Division to EUR...
Loading company panel...



